62089-74-1

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Pyridylmethyl)piperazine is used as a key intermediate in the synthesis of various pharmaceutical drugs for its ability to modulate serotonin receptor activity. It is particularly instrumental in the development of antipsychotic and antihistamine medications, where its antagonistic properties help manage symptoms associated with these conditions.
Used in Industrial Chemical Production:
In the industrial sector, 1-(4-Pyridylmethyl)piperazine serves as a crucial component in the manufacturing of plastics, resins, and rubber additives. Its inclusion in these materials contributes to enhancing their performance characteristics, such as durability and flexibility.
Used in Mental Health Treatment:
1-(4-Pyridylmethyl)piperazine is being studied for its potential as a therapeutic agent for the treatment of depression, anxiety, and other mental health disorders. Its role as a serotonin receptor antagonist suggests that it may help regulate mood and emotional responses, offering a promising avenue for the development of new treatments in psychiatry.
Used in Drug Development Research:
1-(4-Pyridylmethyl)piperazine is also utilized in research settings to explore its potential in drug development. Given its interaction with serotonin receptors, it is a subject of interest for scientists looking to understand and develop new medications that can effectively address a range of mental health conditions.

InChI:InChI=1/C10H15N3/c1-3-11-4-2-10(1)9-13-7-5-12-6-8-13/h1-4,12H,5-9H2

Upstream product

• 120-43-4 4-ethoxycarbonylpiperazine 
• 143210-48-4 4-(4-pyridylmethyl)-1-piperazinecarboxylic acid, ethyl ester 
• 67-63-0 isopropyl alcohol 
• 54751-01-8 4-(bromomethyl)pyridine 
• 150812-38-7 tert-butyl 4-(pyridin-4-ylmethyl)piperazine-1-carboxylate 
• 872-85-5 pyridine-4-carbaldehyde 
• 10445-91-7 4-(Chloromethyl)pyridine 
• 942486-74-0 C₁₂H₁₇N₃O 

Downstream Products

• 617691-12-0 4-(4-pyridin-4-ylmethylpiperazin-1-yl)benzonitrile 
• 438570-13-9 {3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-ethoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone 
• 1018611-69-2 4-(4-pyridin-4-ylmethyl-piperazin-1-yl)-benzoic acid 
• 617691-13-1 3-(4-{[4-(4-pyridin-4-ylmethylpiperazin-1-yl)benzoylamino]methyl}phenyl)acrylic acid ethyl ester 
• 438570-08-2 {3-[2-(2,4-dichlorophenyl)-ethoxy]-4-methyl-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone 
• 1190967-08-8 (E)-3-(2-nitrophenyl)-1-(4-pyridin-4-ylmethylpiperazin-1-yl)propenone 
• 1208253-82-0 N-(5-tert-butyl-2-methylphenyl)-7-methyl-2-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-7H-purin-6-amine 
• 1226860-22-5 6-methylbenzo[b]thiophene-2-carboxylic acid {1-[(S)-1-benzyl-4-(4-pyridin-4-ylmethylpiperazin-1-yl)butylcarbamoyl]cyclopentyl}amide 
• 1258934-94-9 5-(4-fluorophenyl)-2-(4-pyridin-4-ylmethylpiperazin-1-yl)-4H-pyrrolo[2,3-d]thiazole 
• 1258411-05-0 C₂₅H₂₆ClN₉OS 
• 1268619-08-4 C₄₉H₅₈N₈O₉S₃ 

Relevant academic research and scientific papers

Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer

Poly (ADP-ribose) polymerase-1 (PARP-1) is a potential target for the discovery of chemosensitizers and anticancer drugs. Amentoflavone (AMF) is reported to be a selective PARP-1 inhibitor. Here, structural modifications and trimming of AMF have led to a series of AMF derivatives (9a-h) and apigenin-piperazine/piperidine hybrids (14a-p, 15a-p, 17a-h, and 19a-f), respectively. Among these compounds, 15l exhibited a potent PARP-1 inhibitory effect (IC50 = 14.7 nM) and possessed high selectivity to PARP-1 over PARP-2 (61.2-fold). Molecular dynamics simulation and the cellular thermal shift assay revealed that 15l directly bound to the PARP-1 structure. In in vitro and in vivo studies, 15l showed a potent chemotherapy sensitizing effect against A549 cells and a selective cytotoxic effect toward SK-OV-3 cells through PARP-1 inhibition. 15l·2HCl also displayed good ADME characteristics, pharmacokinetic parameters, and a desirable safety margin. These findings demonstrated that 15l·2HCl may serve as a lead compound for chemosensitizers and the (BRCA-1)-deficient cancer therapy.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors

A series of novel 1,4-disubstituted piperidine/piperazine derivatives were designed, synthesized and evaluated for their in vitro activities against HIV-1 Bal (R5) infection in CEMX174 5.25M7 cells. A majority of these compounds showed potent anti-HIV-1 activities with IC50 at nanomolar levels. N-(4-Fluoro-benzyl)piperazine analog B07 hydrochloride exhibited potency against HIV-1 activity similar to that of TAK-220 hydrochloride, but it had much better water solubility (25 mg/ml in phosphate sodium buffer at 25 °C) and oral bioavailability (56%) than TAK-220 hydrochloride (a solubility of 2 mg/ml and oral bioavailability of 1.4%). These results suggest that B07 hydrochloride may serve as a better lead for the development of new anti-HIV-1 therapies or microbicides for treatment and prevent of HIV-1 infection.

Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled hum

TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

A triazole derivative of formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has advantageously low toxicity.

Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors

A series of adamantyl amide 11β-HSD1 inhibitors has been discovered and chemically modified. Selected compounds are selective for 11β-HSD1 over 11β-HSD2 and possess excellent cellular potency in human and murine 11β-HSD1 assays. Good pharmacodynamic characteristics are observed in ex vivo assays.

Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity

Compounds of formula (I) in which the substituents and symbols have the meanings indicated in the description, are suitable for the control of Helicobacter bacteria.

2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines

This disclosure describes novel 2-(4-substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines useful as hypotensive agents.